Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 7.
doi: 10.1002/art.43221. Online ahead of print.

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

Baptiste Chevet  1 , Aghiles Souki  2 , Emmanuel Nowak  2 , Guillermo Carvajal-Alegria  1 , Emmanuelle Dernis  3 , Christophe Richez  4 , Marie-Elise Truchetet  4 , Daniel Wendling  5 , Eric Toussirot  6 , Aleth Perdriger  7 , Jacques-Eric Gottenberg  8 , Renaud Felten  8 , Bruno Fautrel  9 , Anne Lohse  10 , Laurent Chiche  11 , Pascal Hilliquin  12 , Catherine Le Henaff  13 , Benjamin Dervieux  14 , Guillaume Direz  3 , Isabelle Chary-Valckenaere  15 , Divi Cornec  1 , Dewi Guellec  16 , Thierry Marhadour  17 , Alain Saraux  17 , Valérie Devauchelle-Pensec  1
Affiliations

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

Baptiste Chevet et al. Arthritis Rheumatol. .

Abstract

Objective: The SEMAPHORE trial evaluated the efficacy and safety of tocilizumab (TCZ) treatment in patients with glucocorticoid (GC)-dependent polymyalgia rheumatica (PMR). TCZ reduced GC dose and disease activity at week 24. This study aimed to assess relapse rates after stopping TCZ treatment in patients achieving remission at week 24.

Methods: In the randomized study, 101 patients received intravenous TCZ (8 mg/kg) or placebo for 24 weeks. Of the 49 patients treated with TCZ, 33 achieved the primary outcome (PMR activity score <10 and GC dose reduction of ≤5 mg/day or ≥10 mg). All 33 patients except one stopped TCZ treatment at week 24 and completed a visit at week 32, with optional follow-up visits every eight weeks until week 48. Relapse was defined as the failure of the primary composite outcome during follow-up or the need for one or more TCZ infusion. Results were analyzed using Kaplan-Meier curves.

Results: Among the 33 patients who received TCZ in remission at week 24, seven stopped follow-ups before week 48, and two of the remaining 26 patients (7.7%) sustained remission in the following six months. 24 (92.3%) of the total patients experienced a relapse. The median time to relapse was 15 weeks (interquartile range, 8-25 weeks).

Conclusion: Among patients with GC-dependent PMR in remission after a six-month TCZ treatment, only a minority of the patients remained relapse-free after TCZ discontinuation. This study suggests that a six-month treatment course is not long enough to withdraw the TCZ. Further studies are needed to determine the optimal TCZ treatment duration and strategies for cessation to prevent relapses.

PubMed Disclaimer

References

REFERENCES

    1. Wendling D, Al Tabaa O, Chevet B, et al. Recommendations of the French Society of Rheumatology for the management in current practice of patients with polymyalgia rheumatica. Joint Bone Spine 2024;91(4):105730.
    1. Dejaco C, Singh YP, Perel P, et al. European League Against Rheumatism; American College of Rheumatology. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799–1807.
    1. Floris A, Piga M, Chessa E, et al. Long‐term glucocorticoid treatment and high relapse rate remain unresolved issues in the real‐life management of polymyalgia rheumatica: a systematic literature review and meta‐analysis. Clin Rheumatol 2022;41(1):19–31.
    1. Devauchelle‐Pensec V, Carvajal‐Alegria G, Dernis E, et al. Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial. JAMA 2022;328(11):1053–1062.
    1. Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 2004;63(10):1279–1283.

LinkOut - more resources